Approach to Oligometastatic Prostate Cancer
- 1 May 2016
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in American Society of Clinical Oncology Educational Book
- Vol. 35 (36) , 119-129
Abstract
Oligometastatic prostate cancer has increasingly been recognized as a unique clinical state with therapeutic implications. It has been proposed that patients with oligometastases may have a more indolent course and that outcome may be further improved with metastasis-directed local ablative therapy. In addition, there are differing schools of thoughts regarding whether oligometastases represent isolated lesions—where targeted therapy may render a patient disease free—or whether they coexist with micrometastases, where targeted therapy in addition to systemic therapy is required for maximal clinical impact. As such, the approach to the patient with oligometastatic prostate cancer requires multidisciplinary consideration, with surgery, radiotherapy, and systemic therapy potentially of benefit either singularly or in combination. Indeed, mounting evidence suggests durable disease-free intervals and, in some cases, possibly cure, may be achieved with such a multimodal strategy. However, selecting patients that may benefit most from treatment of oligometastases is an ongoing challenge. Moreover, with the advent of new, highly sensitive imaging technologies, the spectrum based on CT of the abdomen and pelvis and technetium bone scan of localized to oligometastatic to widespread disease has become increasingly blurred. As such, new MRI- and PET-based modalities require validation. As some clinical guidelines advise against routine prostate-specific antigen screening, the possibility of more men presenting with locally advanced or de novo oligometastatic prostate cancer exists; thus, knowing how best to treat these patients may become more relevant at a population level. Ultimately, the arrival of prospective clinical data and better understanding of biology will hopefully further inform how best to treat men with this disease.Keywords
This publication has 54 references indexed in Scilit:
- Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional AnalysisEuropean Urology, 2016
- The Pendulum of Prostate Cancer Screening2015
- Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening RecommendationsJAMA, 2015
- The biology and treatment of oligometastatic cancerOncotarget, 2015
- Oligometastases in prostate cancer: restaging stage IV cancers and new radiotherapy optionsRadiation Oncology, 2014
- Oligometastases revisitedNature Reviews Clinical Oncology, 2011
- External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised studyThe Lancet Oncology, 2010
- RADICAL RETROPUBIC PROSTATECTOMY PLUS ORCHIECTOMY VERSUS ORCHIECTOMY ALONE FOR pTxN+ PROSTATE CANCER: A MATCHED COMPARISONJournal of Urology, 1999
- Survival and Quality of Life of Patients with Stage D1 (T1-3 pN1-2 MO) Prostate CancerEuropean Urology, 1995
- Stage D1 prostate cancer. A nonrandomized comparison of conservative treatment options versus radical prostatectomyCancer, 1993